Pharmaceutical sponsorship bias influences thrombolytic literature in acute ischemic stroke

Western Journal of Emergency Medicine

Volumn 12, Issue 4, 2011, Pages 435-441

  Radecki, Ryan Patrick ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 81255179874     PISSN: 1936900X     EISSN: 19369018     Source Type: Journal    
DOI: 10.5811/westjem.2011.5.2166     Document Type: Review

References (51)

1. Truelsena T, Ekmanb M, Boysena G. Cost of stroke in Europe. Eur J Neurol. 2005;12(suppl 1):78-84.
2. Adams HP Jr, Adams RJ, Brott T, et al. Guidelines for the early management of patients with ischaemic stroke: a scientific statement from the Stroke Council of the American Stroke Association. Stroke. 2003;34:1056-1083. (Pubitemid 36402991)
3. The European Stroke Initiative Executive Committee and European Stroke Initiative Writing Group. European stroke initiative recommendations for stroke management: update 2003. Cerebrovasc Dis. 2003;16:311-337.
4. Chan YF, Kwiatkowski TG, Rella JG, et al. Tissue plasminogen activator for acute ischemic stroke: a New York City Emergency Medicine Perspective. J Emerg Med. 2005;29:405-408. (Pubitemid 41501566)
5. Wals M, Fromm G. Emergency physician survey: recombinant tissue plasminogen activator for stroke. Ann Emerg Med. 2005;47:296-297.
6. Goyal DG, Li J, Mann J, et al. Position statement on the use of intravenous thrombolytic therapy in the treatment of stroke. American Academy of Emergency Medicine Web site. Available at: http://www.aaem.org/ positionstatements/thrombolytictherapy.php. Accessed April 2011.
7. ACEP Board of Directors. Use of intravenous tPa for the management of acute stroke in the emergency department. American College of Emergency Physicians Web site. Available at: http://www.acep.org/practres.aspx?id=29834. Accessed April 2011.
8. Lenzer J. Alteplase for stroke: money and optimistic claims buttress the "brain attack" campaign. BMJ. 2002;324:723-726. (Pubitemid 34259150)
9. American Heart Association. Annual Report 1999. Dallas: AHA, 2000.
10. Nissen SE. Can we trust cardiovascular practice guidelines? Arch Intern Med. 2011;171:584-585.
11. Mendelson TB, Meltzer M, Campbell EG, et al. Conflicts of interest in cardiovascular clinical practice guidelines. Arch Intern Med. 2011;171:577-584.
12. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA. 2003;289:454-469.
13. Sismondo S. Pharmaceutical company funding and its consequences: a qualitative systematic review. Cont Clin Trials. 2007;29:109-113. (Pubitemid 351248768)
14. Moed HF. New developments in the use of citation analysis in research evaluation. Arch Immunol Ther Exp. (Warsz) 2009;57:13-18.
15. Pendlebury DA. The use and misuse of journal metrics and other citation indicators. Arch Immunol Ther Exp. (Warsz) 2009;57:1-11.
16. Falagas ME, Pitsouni El, Malietzis R, et al. Comparison of PubMed, Scopus, Web of Science, and Google Scholar: strengths and weaknesses. FASEB J. 2008;22:338-342. (Pubitemid 351225599)
17. Ridker PM, Hennekens CH, Stampfer MJ, et al. Prospective-study of endogenous-tissue plasminogen-activator and risk of stroke. Lancet. 1994;343:940-943. (Pubitemid 24117228)
18. Von Kummer R, Alle KL, Holle R, et al. Acute stroke: usefulness of early CT findings before thrombolytic therapy. Radiology. 1999;205:315-318.
19. Burroughs-Wellcome Fund. Fact sheet. Burroughs-Wellcome Fund Web site. Available at: http://www.bwfund.org/pages/58/Fact-Sheet. Accessed April 2011.
20. Popelut A, Valet F, Fromentin O, et al. Relationship between sponsorship and failure rate of dental implants: a systematic approach. PLoS ONE. 2010;5:e10274.
21. Golder S, Loke Y. Is there evidence for biased report of published adverse effects data in pharmaceutical industry-funded studies? Br J Clin Pharmacol. 2008;66:767-773.
22. Boutron I, Dutton S, Ravaud P, et al. Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA. 2010;303:2058-2064.
23. DeAngelis CD, Fontanarosa PB. Impugning the integrity of medical science: the adverse effects of industry influence. JAMA. 2008;299:1800-1812.
24. Saver J, Kidwell C, Starkman S. Commentary: thrombolysis in stroke it works! BMJ. 2002;324:727-729.
25. Glick M. Whether industry-supported or otherwise, trust is key to the acceptance of all research. JADA. 2010;141:127-128.
26. Del Zoppo GJ, Saver J, Jauch EC, et al. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke. 2009;40:2945-2948.
27. Hoffman J, Schriger DL. A graphical re-analysis of the NINDS Trial. Ann Emerg Med. 2009;54:329-336.
28. Bluhmki E, Chamorro A, Davalos A, et al. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomized controlled trial. Lancet Neurol. 2009;8:1095-1102.
29. Alshekhlee A, Mohammadi A, Mehta S. Is thrombolysis safe in the elderly? Analysis of a national database. Stroke. 2010;41:2259-2264.
30. Sandercock PA, Wardlaw J, Lindley R. Third International Stroke Trial (IST-3). Internet Stroke Center Web site. Available at: http://www.strokecenter. org/trials/TrialDetail.aspx?tid=81. Accessed March 2011.
31. Weintraub M. Thrombolysis (tissue plasminogen activator) in stroke: a medicolegal quagmire. Stroke. 2006;37:1917-1922. (Pubitemid 44297752)
32. [No authors listed]. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333:1581-1587.
33. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017-1025.
34. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA. 1999;282:2003-2011.
35. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebocontrolled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352:1245-1251. (Pubitemid 28470336)
36. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768-774.
37. Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA. 1999;282:2019-2026.
38. Del Zoppo GJ, Poeck K, Pessin MS, et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol. 1992;32:78-86.
39. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
40. Hacke W, Albers G, Al-Rawi Y, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. 2005;36:66-73. (Pubitemid 40054177)
41. Candelise L, Aritzu E, Ciccone A, et al. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischemic stroke. Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Lancet. 1995;346:1509-1514.
42. Katzan IL, Furlan AJ, Lloyd LE, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA. 2000;283:1151-1158. (Pubitemid 30126603)
43. Albers GW, Bates VE, Clark WM, et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA. 2000;283:1145-1150. (Pubitemid 30126602)
44. Alexandrov AV, Molina CA, Grotta JC, et al. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med. 2004;351:2170-2180.
45. Marler JR, Tilley BC, Lu M, et al. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology. 2000;55:1649-1655.
46. Brott TG, Haley EC Jr, Levy DE, et al. Urgent therapy for stroke. Part I. Pilot-study of tissue plasminogen activator administered within 90 minutes. Stroke. 1992;23:632-640.
47. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369:275-282. (Pubitemid 46138121)
48. Hommel M, Cornu C, Boutitie F, et al. Thrombolytic therapy with streptokinase in acute ischemic stroke. The Multicenter Acute Stroke Trial-Europe Study Group. N Engl J Med. 1996;335:145-150. (Pubitemid 26249450)
49. Mori E, Yoneda Y, Tabuchi M, et al. Intravenous recombinant tissue plasminogen-activator in acute carotid-artery territory stroke. Neurology. 1992;42:976-982.
50. Lewandowski CA, Frankel M, Tomsick TA, et al. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke. 1999;30:2598-2605.
51. Donnan GA, Davis SM, Chambers BR, et al. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. JAMA. 1996;276:961-966. (Pubitemid 26318225)